<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f3b30f0-e48d-2de1-e063-6394a90a1b69"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Uretron D/S</title>
   <effectiveTime value="20250228"/>
   <setId root="ea74f1aa-2b4d-4ccf-e053-2995a90abab5"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="076007996"/>
            <name>DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f3b5eec-6606-41f8-e063-6394a90ab31a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="12539-144" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Uretron D/S</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J9EQA3S2JM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="40.8"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="36.2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="28A37T47QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENYL SALICYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="28A37T47QO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENYL SALICYLATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.12"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F2R8V82B84" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYOSCYAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PX44XO846X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYOSCYAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10.8"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="T42P99266K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLENE BLUE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="ZMZ79891ZH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLENE BLUE CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="81.6"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="J50OIX95QV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHENAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J50OIX95QV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHENAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12539-144-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20221007"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221007"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SAT;902</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b71-25b6-e063-6294a90a57d0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section ID="id_link_ea753e47-1d89-8134-e053-2995a90a8f31">
               <id root="17b7aaf8-7b72-25b6-e063-6294a90a57d0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Uretron
  
   <sup>™</sup>D/S
 
  </content>tablets for oral administration

 </paragraph>
                  <table width="50%">
                     <col align="left" valign="top" width="75%"/>
                     <col align="right" valign="top" width="25%"/>
                     <tbody>
                        <tr styleCode="toprule">
                           <td>Each tablet contains:</td>
                           <td/>
                        </tr>
                        <tr>
                           <td>Methenamine</td>
                           <td>81.6 mg</td>
                        </tr>
                        <tr>
                           <td>Sodium Phosphate Monobasic</td>
                           <td>40.8 mg</td>
                        </tr>
                        <tr>
                           <td>Phenyl Salicylate</td>
                           <td>36.2 mg</td>
                        </tr>
                        <tr>
                           <td>Methylene Blue</td>
                           <td>10.8 mg</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td>Hyoscyamine Sulfate</td>
                           <td>0.12 mg</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>HYOSCYAMINE SULFATE. [620-61-1][3(S)-endo]-α-(Hydroxymethyl)-benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester sulfate(2:1)(salt); 1αH,5αH-tropan-3α-ol(-)-tropate(ester) sulfate(2:1)(salt);3α-tropanyl S-(-)-tropate; l-tropic acid ester with tropine; l-tropine tropate. C
 
  <sub>34</sub>H
 
  <sub>48</sub>N
 
  <sub>2</sub>O
 
  <sub>10</sub>S. Hyoscyamine Sulfate is an alkaloid of belladonna. Exists as a white crystalline powder. Its solutions are alkaline to litmus. Affected by light, it is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether.

 </paragraph>
                  <paragraph>METHENAMINE. [100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1
 
  <sup>3,7</sup>] decane; hexamethylenetetramine; HMT; HMTA; hexamine; 1,3,5,7-tetraazaadamantane hexamethylenemine; Uritone; Urotropin. C
 
  <sub>6</sub>H
 
  <sub>12</sub>N
 
  <sub>4</sub>; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine (hexamethylenetetramine) exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water, soluble in alcohol and in chloroform.

 </paragraph>
                  <paragraph>METHYLENE BLUE. [61-73-4] 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride; C.I. Basic Blue 9; methylthioninium chloride; tetramethylthionine chloride; 3,7-bis(dimethylamino) phenazathionium chloride. C
 
  <sub>16</sub>H
 
  <sub>18</sub>ClN
 
  <sub>3</sub>S; mol wt 319.85, C 60.08%, H 5.67%, Cl 11.08%, N 13.14%, S 10.03%. Methylene Blue (Methylthionine chloride) exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.

 </paragraph>
                  <paragraph>PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C
 
  <sub>13</sub>H
 
  <sub>10</sub>O
 
  <sub>3</sub>; mol wt 214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus oxy-chloride on a mixture of phenol and salicylic acid. Phenyl Salicylate exists as white crystals with a melting point of 41°-43° C. It is very slightly soluble in water and freely soluble in alcohol.

 </paragraph>
                  <paragraph>SODIUM PHOSPHATE MONOBASIC. [7558-80-7] Phosphoric acid sodium salt (1:1); Sodium biphosphate; sodium dihydrogen phosphate; acid sodium phosphate; monosodium orthophosphate; primary sodium phosphate; H
 
  <sub>2</sub>NaO
 
  <sub>4</sub>P; mol wt 119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%. Monohydrate, white, odorless slightly deliquesce crystals or granules. At 100° C loses all its water; when ignited it converts to metaphosphate. It is freely soluble in water and practically insoluble in alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous solution at 25° C: 4.5.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Uretron D/S</content>tablets contain inactive ingredients: Crospovidone, Dicalcium Phosphate, FD&amp;C Blue #1 Aluminum Lake, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Stearic Acid, Talc, and Titanium Dioxide.

 </paragraph>
               </text>
               <effectiveTime value="20221007"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b73-25b6-e063-6294a90a57d0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>HYOSCYAMINE SULFATE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout the body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate.</paragraph>
                  <paragraph>METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70%-90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this at a pH of 5, approximately 20% is formaldehyde. Protein binding - some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.</paragraph>
                  <paragraph>METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed by the gastrointestinal tract and rapidly reduced to leukomethylene blue which is stabilizied in some combination form in the urine. 75% is excreted unchanged.</paragraph>
                  <paragraph>PHENYL SALICYLATE releases salicylate, a mild analgesic for pain.</paragraph>
                  <paragraph>SODIUM PHOSPHATE MONOBASIC an acidifier, helps to maintain an acid pH in the urine necessary for the degradation of methenamine.</paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section ID="id_link_ea7539f8-13c8-9f79-e053-2a95a90a7a99">
               <id root="17b7aaf8-7b74-25b6-e063-6294a90a57d0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Uretron D/S</content>tablets are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

 </paragraph>
               </text>
               <effectiveTime value="20221007"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b75-25b6-e063-6294a90a57d0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Hypersensitivity to any of the ingredients is possible.</paragraph>
                  <paragraph>Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).</paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b76-25b6-e063-6294a90a57d0"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs discontinue use immediately.</paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b77-25b6-e063-6294a90a57d0"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20100830"/>
               <component>
                  <section ID="id_link_ea75709b-50dc-3224-e053-2a95a90a03b2">
                     <id root="17b7aaf8-7b78-25b6-e063-6294a90a57d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cross sensitivity and/or related problems</title>
                     <text>
                        <paragraph>Patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers.</paragraph>
                     </text>
                     <effectiveTime value="20100830"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="17b7aaf8-7b79-25b6-e063-6294a90a57d0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy/Reproduction</title>
                     <effectiveTime value="20100830"/>
                     <component>
                        <section ID="id_link_ea7539f8-13cc-9f79-e053-2a95a90a7a99">
                           <id root="17b7aaf8-7b7a-25b6-e063-6294a90a57d0"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>FDA Pregnancy Category C</title>
                           <text>
                              <paragraph>Hyoscyamine and methenamine cross the placenta. Studies concerning the effect of hyoscyamine and methenamine on pregnancy and reproduction have not been done in animals or humans. Thus it is not known whether
 
  <content styleCode="bold">Uretron D/S</content>tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
 
  <content styleCode="bold">Uretron D/S</content>should be given to a pregnant woman only if clearly needed.

 </paragraph>
                           </text>
                           <effectiveTime value="20221007"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="id_link_ea75357c-1966-7812-e053-2a95a90acde1">
                     <id root="17b7aaf8-7b7b-25b6-e063-6294a90a57d0"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Breast feeding</title>
                     <text>
                        <paragraph>Problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk. Accordingly,
 
  <content styleCode="bold">Uretron D/S</content>tablets should be given to a nursing mother with caution and only if clearly needed.

 </paragraph>
                     </text>
                     <effectiveTime value="20100830"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_ea7580a7-613b-7ffb-e053-2a95a90a7fc2">
                     <id root="17b7aaf8-7b7c-25b6-e063-6294a90a57d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Prolonged use</title>
                     <text>
                        <paragraph>There have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to valuate carcinogenic potential.</paragraph>
                     </text>
                     <effectiveTime value="20100830"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_ea7578b7-e2f0-962d-e053-2995a90ac45a">
                     <id root="17b7aaf8-7b7d-25b6-e063-6294a90a57d0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric</title>
                     <text>
                        <paragraph>Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.</paragraph>
                     </text>
                     <effectiveTime value="20100830"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_ea7580a7-613d-7ffb-e053-2a95a90a7fc2">
                     <id root="17b7aaf8-7b7e-25b6-e063-6294a90a57d0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Use with caution in elderly patients as they may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness or confusion.</paragraph>
                     </text>
                     <effectiveTime value="20100830"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_ea754e5e-66e9-f356-e053-2995a90a6b13">
               <id root="17b7aaf8-7b7f-25b6-e063-6294a90a57d0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Cardiovascular: rapid heartbeat, flushing</paragraph>
                  <paragraph>Central Nervous System: blurred vision, dizziness, drowsiness</paragraph>
                  <paragraph>Genitourinary: difficult micturition, acute urinary retention</paragraph>
                  <paragraph>Gastrointestinal: dry mouth, nausea and vomiting</paragraph>
                  <paragraph>Respiratory: shortness of breath or trouble breathing</paragraph>
                  <paragraph>Serious allergic reactions to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing.</paragraph>
                  <paragraph>This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor or physician for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact A.G. Marin Pharmaceuticals at 305-593-5333 or FDA at 1-800-FDA-1088, www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20221007"/>
               <component>
                  <section ID="id_link_ea757d48-1216-9620-e053-2995a90a0ab5">
                     <id root="17b7aaf8-7b80-25b6-e063-6294a90a57d0"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug interactions</title>
                     <text>
                        <paragraph>As a result of hyoscyamine's effects on gastrointestinal motility and gastric emptying, absorption of other oral medications may be decreased during concurrent use with this combination medication. 
  <br/>  Methylene blue inhibits a range of CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5. This interaction could be more pronounced with narrow therapeutic index drugs that are metabolized by one of these enzymes (e.g., digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus). However, the clinical relevance of these in vitro interactions is unknown. 
  <br/>
                           <content styleCode="bold">Urinary alkalizers and thiazide diuretics:</content>May cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. 
  <br/>
                           <content styleCode="bold">Antimuscarinics</content>: Concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications. 
  <br/>
                           <content styleCode="bold">Antacids/antidiarrheals:</content>Concurrent use may reduce absorption of hyoscyamine resulting in decreased therapeutic effectiveness. Concurrent use with antacids may cause urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. Doses of these medications should be spaced 1 hour apart from doses of hyoscyamine. 
  <br/>
                           <content styleCode="bold">Antimyasthenics:</content>Concurrent use with hyoscyamine may further reduce intestinal motility, therefore, caution is recommended. 
  <br/>  Ketoconazole and hyoscyamine may cause increased gastrointestinal pH. Concurrent administration with hyoscyamine may result in marked reduction in the absorption of ketoconazole. Patients should be advised to take this combination at least 2 hours 
  <br/>  after ketoconazole. 
  <br/>
                           <content styleCode="bold">Monoamine oxidase (MAO) inhibitors:</content>Concurrent use with hyoscyamine may intensify antimuscarinic side effects. 
  <br/>  Opioid (narcotic) analgesics may result in increased risk of severe constipation. 
  <br/>
                           <content styleCode="bold">Sulfonamides:</content>These drugs may precipitate with formaldehyde in the urine increasing the danger of crystalluria. 
  <br/>  Patients should be advised that the urine and/or stools may become blue to blue-green as a result of the excretion of methylene blue.

 </paragraph>
                     </text>
                     <effectiveTime value="20221007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_ea754e5e-667c-f356-e053-2995a90a6b13">
               <id root="17b7aaf8-7b81-25b6-e063-6294a90a57d0"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph>A dependence on the use of Uretron D/S tablets has not been reported and due to the nature of its ingredients, abuse of Uretron D/S tablets is not expected.</paragraph>
               </text>
               <effectiveTime value="20221007"/>
            </section>
         </component>
         <component>
            <section>
               <id root="17b7aaf8-7b82-25b6-e063-6294a90a57d0"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms.</paragraph>
                  <paragraph>Administration of small doses of diazepam to control excitement and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary.</paragraph>
                  <paragraph>If overdose is suspected, contact your local poison center or emergency room immediately. US residents can contact the US National Poison Hotline at 1-800-222-1222.</paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section ID="id_link_ea759a0f-c0cf-9622-e053-2995a90af479">
               <id root="17b7aaf8-7b83-25b6-e063-6294a90a57d0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Adults - O</content>ne tablet orally 4 times per day followed by liberal fluid intake.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Older Children -</content>Dosage must be individualized by physician. Not recommended for use in children six years of age or younger.

 </paragraph>
               </text>
               <effectiveTime value="20100830"/>
            </section>
         </component>
         <component>
            <section ID="id_link_46e3b17c-53e8-6082-e054-00144ff8d46c">
               <id root="17b7aaf8-7b84-25b6-e063-6294a90a57d0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Uretron D/S</content>tablets are blue tablets imprinted with "SAT" on one side and "902" on opposite side.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC</content>12539-144-01, Bottle of 100 Tablets.

 </paragraph>
               </text>
               <effectiveTime value="20221007"/>
               <component>
                  <section ID="id_link_ea75677e-b3bb-15c3-e053-2995a90ae3e4">
                     <id root="17b7aaf8-7b85-25b6-e063-6294a90a57d0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>STORAGE</title>
                     <text>
                        <paragraph>Dispense in a tight, light-resistant container as defined in the USP/NF with a child resistant closure.</paragraph>
                        <paragraph>Store at controlled room temperature 20°-25°C (68°-77°F).</paragraph>
                        <paragraph>Keep in a cool, dry place. Keep container tightly closed.</paragraph>
                     </text>
                     <effectiveTime value="20221007"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_4579cb79-0ae6-6ee3-e054-00144ff8d46c">
                     <id root="17b7aaf8-7b86-25b6-e063-6294a90a57d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Keep this and all drugs out of reach of children.</content>
                        </paragraph>
                        <paragraph>Rx Only</paragraph>
                        <paragraph/>
                        <paragraph>Manufactured for: 
  <br/>  A.G. MARIN PHARMACEUTICALS 
  <br/>  P.O. BOX 174 
  <br/>  MIAMI, FL 33144
 </paragraph>
                     </text>
                     <effectiveTime value="20221007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_458dac54-248c-6937-e054-00144ff88e88">
               <id root="17b7aaf8-7b87-25b6-e063-6294a90a57d0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Uretron D/S Bottle Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_ea75c77e-12e7-26f0-e053-2a95a90a6542"/>
                  </paragraph>
               </text>
               <effectiveTime value="20221007"/>
               <component>
                  <observationMedia ID="img_ea75c77e-12e7-26f0-e053-2a95a90a6542">
                     <text>Uretron</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Uretron DS 100ct label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>